Navigation

Multiple myeloma - bortezomib (consolidation therapy) [ID529]

Bortezomib for consolidation therapy after autologous stem cell transplantation for the treatment of multiple myeloma

Status: In development
Expected date of issue: TBC
Referral date: May 2012
Process: STA
Notes:

Scoped as part of Batch 22

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
20 July 2012 Please note that following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.
Top


 

Key documents

This page was last updated: 23 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.